SUVEN PHARMACEUTICALS LIMITED Financials Suven Pharmaceuticals Limited Bombay S.E.
Equities
SUVENPHAR
INE03QK01018
Pharmaceuticals
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 671.2 INR | +0.25% |
|
+2.02% | -7.57% |
| Mar. 27 | Suven Pharmaceuticals Limited Announces Shifting of Registered Office | CI |
| Mar. 05 | Transcript : Cohance Lifesciences Limited, Suven Pharmaceuticals Limited - M&A Call |
Valuation
| Fiscal Period: March | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 25,590 | 126,468 | 157,436 | 171,093 | 171,093 | - |
| Enterprise Value (EV) 1 | 25,590 | 126,468 | 157,436 | 120,256 | 171,093 | 171,093 |
| P/E ratio | 16.1 x | 34.9 x | 34.7 x | 29.2 x | 51.1 x | 43.4 x |
| Yield | - | 0.4% | 0.32% | 0.35% | 0.26% | 0.26% |
| Capitalization / Revenue | - | 12.5 x | 11.9 x | 8.97 x | 15.7 x | 13 x |
| EV / Revenue | - | 12.5 x | 11.9 x | 8.97 x | 15.7 x | 13 x |
| EV / EBITDA | - | 28.7 x | 27.2 x | 21.2 x | 39 x | 29.8 x |
| EV / FCF | - | 176 x | 61.8 x | 72.8 x | - | - |
| FCF Yield | - | 0.57% | 1.62% | 1.37% | - | - |
| Price to Book | - | 10.7 x | 10.3 x | 6.93 x | 8.43 x | 7.23 x |
| Nbr of stocks (in thousands) | 254,565 | 254,565 | 254,565 | 254,565 | 254,565 | - |
| Reference price 2 | 100.5 | 496.8 | 618.4 | 672.1 | 672.1 | 672.1 |
| Announcement Date | 6/18/20 | 6/8/21 | 5/9/22 | 5/25/23 | - | - |
1INR in Million2INR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: March | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | 10,097 | 13,202 | 13,403 | 10,898 | 13,210 |
| EBITDA 1 | - | 4,405 | 5,794 | 5,665 | 4,392 | 5,740 |
| EBIT 1 | - | 4,088 | 6,738 | 5,652 | 4,360 | 4,900 |
| Operating Margin | - | 40.49% | 51.04% | 42.17% | 40.01% | 37.09% |
| Earnings before Tax (EBT) 1 | - | 4,139 | 6,676 | 5,597 | 4,484 | 5,270 |
| Net income 1 | - | 3,623 | 4,538 | 4,113 | 3,342 | 3,900 |
| Net margin | - | 35.89% | 34.37% | 30.69% | 30.66% | 29.52% |
| EPS 2 | 6.230 | 14.23 | 17.83 | 16.16 | 13.15 | 15.50 |
| Free Cash Flow 1 | - | 720.4 | 2,548 | 1,651 | - | - |
| FCF margin | - | 7.13% | 19.3% | 12.32% | - | - |
| FCF Conversion (EBITDA) | - | 16.35% | 43.98% | 29.15% | - | - |
| FCF Conversion (Net income) | - | 19.88% | 56.15% | 40.15% | - | - |
| Dividend per Share 2 | - | 2.000 | 2.000 | 2.350 | 1.750 | 1.750 |
| Announcement Date | 6/18/20 | 6/8/21 | 5/9/22 | 5/25/23 | - | - |
1INR in Million2INR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: March | 2021 Q2 | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 2,377 | 2,749 | 2,592 | 2,638 | 3,060 | 3,916 | 3,638 | 3,388 | 2,784 | 3,538 | 3,694 | 3,431 | 3,025 | 3,045 |
| EBITDA 1 | 984.9 | 1,381 | 936.9 | 1,146 | 1,218 | 1,860 | 1,570 | 1,509 | 998.8 | 1,467 | 1,691 | 1,416 | - | 1,208 |
| EBIT | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net income 1 | 740.8 | 1,136 | 831.2 | 1,051 | 969.8 | 1,601 | 916.7 | 1,075 | 720.6 | 1,077 | 1,240 | 1,044 | 913 | 906 |
| Net margin | 31.16% | 41.33% | 32.07% | 39.83% | 31.69% | 40.88% | 25.19% | 31.74% | 25.88% | 30.45% | 33.56% | 30.43% | 30.18% | 29.75% |
| EPS | - | - | - | 4.130 | 3.810 | - | 3.600 | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 10/30/20 | 2/10/21 | 6/8/21 | 8/16/21 | 11/6/21 | 2/8/22 | 5/9/22 | 8/8/22 | 11/8/22 | 2/6/23 | 5/25/23 | - | - | - |
1INR in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - |
| Net Cash position | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | 720 | 2,548 | 1,651 | - | - |
| ROE (net income / shareholders' equity) | 35.8% | 33.5% | 25.2% | 17.7% | 17.8% |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets 1 | - | - | - | - | - |
| Book Value Per Share 2 | 46.40 | 60.00 | 68.20 | 79.70 | 93.00 |
| Cash Flow per Share | - | - | - | - | - |
| Capex 1 | 1,108 | 752 | 2,858 | 1,585 | 1,900 |
| Capex / Sales | 10.98% | 5.7% | 21.32% | 14.54% | 14.38% |
| Announcement Date | 6/8/21 | 5/9/22 | 5/25/23 | - | - |
1INR in Million2INR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D-
Sell
Buy
Mean consensus
HOLD
Number of Analysts
2
Last Close Price
672.1
INR
Average target price
685.5
INR
Spread / Average Target
+1.99%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +21.85% | 546B | |
| -4.77% | 359B | |
| +16.97% | 323B | |
| +5.69% | 290B | |
| +13.68% | 234B | |
| +3.65% | 198B | |
| -11.12% | 194B | |
| +8.08% | 167B | |
| -3.40% | 157B |
- Stock Market
- Equities
- SUVENPHAR Stock
- SUVENPHAR Stock
- Financials Suven Pharmaceuticals Limited
